---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006764"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:37:42.834947+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioCardia granted Japanese patent for Helix biotherapeutic delivery catheter expiring 2034

## Summary
- Japan Patent Office issued Patent No. 7641330 titled 'Radial and Transendocardial Delivery Catheter'.
- Patent term expires on or after September 30, 2034; covers helical needle-tipped catheter platform.
- BioCardia CEO cites growing IP position for cell/gene therapy delivery; Japan is important initial market.
- Helix System is the only catheter-based intramyocardial delivery system in active clinical use per BioCardia.

## SEC filing metadata
- accession: 0001437749-25-006764
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925006764/0001437749-25-006764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925006764/bcda20250308_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006764
- JSON: https://secwatch.observer/filing/0001437749-25-006764.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.